Winton Group LTD Vaxart, Inc. Transaction History

Winton Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.71 - $1.25 $4,042 - $7,116	5,693 Added 21.99%	31,578 $23,000
Q4 2022 Feb 14, 2023	BUY	$0.75 - $2.24 $1,413 - $4,220	1,884 Added 7.85%	25,885 $24,000
Q3 2022 Nov 10, 2022	SELL	$2.09 - $4.5 $277 - $598	-133 Reduced 0.55%	24,001 $52,000
Q2 2022 Aug 10, 2022	BUY	$2.7 - $5.28 $19,329 - $37,799	7,159 Added 42.17%	24,134 $84,000
Q1 2022 May 11, 2022	BUY	$4.29 - $6.64 $24,371 - $37,721	5,681 Added 50.3%	16,975 $86,000
Q4 2021 Feb 10, 2022	SELL	$5.77 - $7.96 $931,716 - $1.29 Million	-161,476 Reduced 93.46%	11,294 $71,000
Q3 2021 Oct 28, 2021	SELL	$6.67 - $9.8 $312,349 - $458,924	-46,829 Reduced 21.32%	172,770 $1.37 Million
Q2 2021 Aug 10, 2021	BUY	$5.06 - $10.78 $269,713 - $574,606	53,303 Added 32.05%	219,599 $1.65 Million
Q1 2021 Jul 21, 2021	BUY	$5.64 - $23.33 $579,256 - $2.4 Million	102,705 Added 161.51%	166,296 $1.01 Million
Q4 2020 Feb 12, 2021	SELL	$3.5 - $7.98 $101,405 - $231,204	-28,973 Reduced 31.3%	63,591 $363,000
Q3 2020 Oct 30, 2020	BUY	$4.78 - $16.97 $442,455 - $1.57 Million	92,564 New	92,564 $616,000

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.